2018 was a incredible boom year in the number of new biotech offerings. Author explores the data around post-IPO market performance and the challenging end of year in the stock market.
Category: NASDAQ:RUBY
2018 was a incredible boom year in the number of new biotech offerings. Author explores the data around post-IPO market performance and the challenging end of year in the stock market.